Ritlecitinib

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

— → —

NCT ID

NCT05522556

About Ritlecitinib

Ritlecitinib is a pre-clinical stage product being developed by Pfizer for Alopecia Areata. The current trial status is active. This product is registered under clinical trial identifier NCT05522556. Target conditions include Alopecia Areata.

What happened to similar drugs?

1 of 20 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (19)

🔄CTP-543Sun PharmaceuticalPhase 3

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05522556	Pre-clinical	Active	—	—	Alopecia Areata
NCT07226531	Pre-clinical	Recruiting	Feb 16, 2026	Mar 31, 2026	Alopecia Areata
NCT07200128	Pre-clinical	Completed	Feb 3, 2025	May 30, 2025	Severe Alopecia Areata
NCT06373458	Phase 2	Recruiting	Aug 13, 2024	Aug 1, 2027	Keloid
NCT06531109	Pre-clinical	Recruiting	Aug 7, 2024	Mar 31, 2028	Alopecia Areata
NCT06369454	Phase 1	Completed	May 3, 2024	Jul 31, 2024	Healthy Volunteers
NCT06172348	Phase 1	Completed	Feb 1, 2024	Mar 28, 2024	Healthy Volunteers
NCT05879458	Phase 2	Terminated	May 17, 2023	Jun 25, 2025	CTCL
NCT05852340	Phase 1	Completed	May 9, 2023	Jul 24, 2023	Healthy Volunteers

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	42
CTP-543	Sun Pharmaceutical	Phase 2/3	42
CTP-543	Sun Pharmaceutical	Phase 3	40
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Upadacitinib + Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47
Ritlecitinib	Pfizer	Pre-clinical	26